| 12/06/25 | GSK | 11:00:00 | 12 Jun 2025 | | GSK | Director/PDMR Shareholding | GSK plc | PRN |
| 16/06/23 | GSK | 07:00:05 | 16 Jun 2023 | | GSK | Extension of FDA review period for momelotinib | GSK PLC | RNS |
| 12/06/23 | GSK | 15:30:00 | 12 Jun 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 07/06/23 | GSK | 07:00:02 | 7 Jun 2023 | | GSK | EU authorisation of GSK’s RSV vaccine Arexvy | GSK PLC | RNS |
| 06/06/23 | GSK | 07:00:02 | 6 Jun 2023 | | GSK | GSK receives US FDA file acceptance for Jemperli | GSK PLC | RNS |
| 01/06/23 | GSK | 15:00:01 | 1 Jun 2023 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 22/05/23 | GSK | 15:30:00 | 22 May 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 15/05/23 | GSK | 15:30:01 | 15 May 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 15/05/23 | GSK | 15:00:01 | 15 May 2023 | | GSK | Block listing Interim Review | GSK PLC | RNS |
| 12/05/23 | GSK | 15:30:01 | 12 May 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 12/05/23 | GSK | 09:50:01 | 12 May 2023 | | GSK | MenABCWY vaccine preliminary phase III results | GSK PLC | RNS |
| 12/05/23 | GSK | 07:05:01 | 12 May 2023 | | GSK | Statement: Zantac Litigation Update BC Canada | GSK PLC | RNS |
| 12/05/23 | GSK | 07:00:01 | 12 May 2023 | | GSK | GSK completes sale of shares in Haleon plc | GSK PLC | RNS |
| 11/05/23 | GSK | 16:41:53 | 11 May 2023 | | GSK | GSK announces intention to sell shares in Haleon | GSK PLC | RNS |
| 09/05/23 | GSK | 15:30:06 | 9 May 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 04/05/23 | GSK | 15:30:01 | 4 May 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 03/05/23 | GSK | 18:20:01 | 3 May 2023 | | GSK | Result of AGM | GSK PLC | RNS |
| 03/05/23 | GSK | 18:00:17 | 3 May 2023 | | GSK | US FDA approves GSK’s RSV vaccine for older adults | GSK PLC | RNS |
| 03/05/23 | GSK | 09:09:16 | 3 May 2023 | | GSK | Form 8.3 - Allergy Therapeutics plc | GSK PLC | RNS |
| 02/05/23 | GSK | 15:00:01 | 2 May 2023 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 28/04/23 | GSK | 17:01:14 | 28 Apr 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 27/04/23 | GSK | 07:00:02 | 27 Apr 2023 | | GSK | GSK RSV OA vaccine gains positive EMA CHMP opinion | GSK PLC | RNS |
| 26/04/23 | GSK | 07:00:09 | 26 Apr 2023 | | GSK | 1st Quarter Results | GSK PLC | RNS |
| 25/04/23 | GSK | 07:00:05 | 25 Apr 2023 | | GSK | EMA validates Jemperli filing for new indication | GSK PLC | RNS |
| 20/04/23 | GSK | 15:30:01 | 20 Apr 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 19/04/23 | GSK | 15:30:01 | 19 Apr 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 18/04/23 | GSK | 07:00:01 | 18 Apr 2023 | | GSK | GSK reaches agreement to acquire BELLUS Health Inc | GSK PLC | RNS |
| 17/04/23 | GSK | 15:30:00 | 17 Apr 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 17/04/23 | GSK | 07:00:04 | 17 Apr 2023 | | GSK | Gepotidacin positive phase III data | GSK PLC | RNS |
| 03/04/23 | GSK | 15:00:01 | 3 Apr 2023 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 28/03/23 | GSK | 07:00:07 | 28 Mar 2023 | | GSK | Positive phase III RUBY results for Jemperli | GSK PLC | RNS |
| 27/03/23 | GSK | 13:00:04 | 27 Mar 2023 | | GSK | Publication of 2023 AGM Notice | GSK PLC | RNS |
| 24/03/23 | GSK | 09:59:11 | 24 Mar 2023 | | GSK | Statement: Zantac (ranitidine) litigation | GSK PLC | RNS |
| 21/03/23 | GSK | 15:30:00 | 21 Mar 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 20/03/23 | GSK | 15:30:01 | 20 Mar 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 14/03/23 | GSK | 07:05:01 | 14 Mar 2023 | | GSK | Positive phase III results for MenABCWY vaccine | GSK PLC | RNS |
| 14/03/23 | GSK | 07:00:02 | 14 Mar 2023 | | GSK | Nucala NDA accepted for review in China | GSK PLC | RNS |
| 13/03/23 | GSK | 15:30:01 | 13 Mar 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 10/03/23 | GSK | 16:26:07 | 10 Mar 2023 | | GSK | GSK Annual Report 2022 on Form 20-F | GSK PLC | RNS |
| 10/03/23 | GSK | 10:36:26 | 10 Mar 2023 | | GSK | GSK publishes Annual Report 2022 | GSK PLC | RNS |
| 02/03/23 | GSK | 07:00:02 | 2 Mar 2023 | | GSK | FDA Ad Com votes to support GSK RSV OA vaccine | GSK PLC | RNS |
| 01/03/23 | GSK | 15:00:01 | 1 Mar 2023 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 27/02/23 | GSK | 15:30:02 | 27 Feb 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 23/02/23 | GSK | 15:30:00 | 23 Feb 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 23/02/23 | GSK | 07:00:09 | 23 Feb 2023 | | GSK | ViiV Healthcare announces Cabenuva positive data | GSK PLC | RNS |
| 22/02/23 | GSK | 15:30:02 | 22 Feb 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 16/02/23 | GSK | 07:00:01 | 16 Feb 2023 | | GSK | NEJM publishes GSK RSV OA vaccine candidate trial | GSK PLC | RNS |
| 15/02/23 | GSK | 16:04:17 | 15 Feb 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 15/02/23 | GSK | 16:00:01 | 15 Feb 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 14/02/23 | GSK | 07:00:01 | 14 Feb 2023 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |